Level C· Early human research exploring benefitsProspective StudyEurope PMC

Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation

Varma V., Yao-Borengasser A., Rasouli N., Bodles AM., Phanavanh B., Lee MJ.

Prospective Study on Type 2 Diabetes, published in J Clin Endocrinol Metab (2007) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Clin Endocrinol Metab (2007)
Reported sample size
—
Source database
Europe PMC
PMID
17090638
PMCID
PMC2893416
DOI
10.1210/jc.2006-1303
Citations
136

Abstract (original English)

Context Visfatin (VF) is a recently described adipokine preferentially secreted by visceral adipose tissue (VAT) with insulin mimetic properties. Objective The aim of this study was to examine the association of VF with insulin sensitivity, intramyocellular lipids (IMCL), and inflammation in humans. Design and patients VF mRNA was examined in paired samples of VAT and abdominal sc adipose tissue (SAT) obtained from subjects undergoing surgery. Plasma VF and VF mRNA was also examined in SAT and muscle tissue, obtained by biopsy from well-characterized subjects with normal or impaired glucose tolerance, with a wide range in body mass index (BMI) and insulin sensitivity (S(I)). Setting The study was conducted at a University Hospital and General Clinical Research Center. Intervention S(I) was measured, and fat and muscle biopsies were performed. In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin. Main outcome measures We measured the relationship between VF and obesity, S(I), adipose tissue inflammation, IMCL, and response to insulin sensitizers. Results No significant difference in VF mRNA was seen between SAT and VAT depots. VAT VF mRNA associated positively with BMI, whereas SAT VF mRNA decreased with BMI. SAT VF correlated positively with S(I), and the association of SAT VF mRNA with S(I) was indepe

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Muscle, SkeletalHumansGlucose IntoleranceInsulin ResistanceObesityInflammationMetforminThiazolidinedionesRNA, MessengerCytokines

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research